Susquehanna International Group
GDTC icon

Susquehanna International Group’s CytoMed Therapeutics GDTC Stock Holding History

Susquehanna International Group’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,829
Closed -$39.7K – 13488
2025
Q4 		$39.7K Buy
+29,829
New +$57.8K ﹤0.01% 11825

Other funds holding GDTC

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's GDTC Position: Q1 2026 in Review

Susquehanna International Group sold out of CytoMed Therapeutics (GDTC) in Q1 2026, closing a stake of 29,829 shares — an estimated $39.7K sold.

Susquehanna International Group first reported a position in GDTC in Q4 2025 and held it in 1 quarter. The position peaked at $39.7K in Q4 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q1 2026.

  • Susquehanna International Group reported no remaining CytoMed Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 29,829 CytoMed Therapeutics shares in Q1 2026, an estimated $39.7K.
  • Susquehanna International Group first reported a position in CytoMed Therapeutics in Q4 2025 and held it in 1 quarter.
  • Susquehanna International Group's CytoMed Therapeutics position peaked at $39.7K in Q4 2025.
  • 3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.